



October 2024

NASDAQ: ACCD

Accolade Inc.

Investor Presentation

This presentation contains "forward-looking statements" –that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "guidance," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or similar expressions. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: our ability to achieve or maintain profitability; our reliance on a limited number of customers for a substantial portion of our revenue; our expectations and management of future growth; our market opportunity and our ability to estimate the size of our target market; the effects of increased competition as well as innovations by new and existing competitors in our market; and our ability to retain our existing customers and to increase our number of customers. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key customers or partners; (v) the impact of COVID-19 on our business and results of operation; and (vi) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2024, Annual Report on Form 10-K for the fiscal year ended February 29, 2024 and subsequent reports that we file.


This presentation includes non-GAAP financial measures. These non-GAAP financial measures are in addition to, and not a substitute for or superior to measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures. For example, other companies may calculate similarly-titled non-GAAP financial measures differently. Refer to the Appendix for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures.



Building a customer-obsessed, nationwide healthcare delivery

company





Investment Highlights

Consistent revenue growth with increasing profitability

Market leader in highly underpenetrated Personalized Healthcare market


High revenue visibility and customer diversification

Integrated platform enables scale, utilization, and margin expansion

Massive opportunity to leverage AI and healthcare tech to transform healthcare experience for all employers and millions of consumers



What stands us apart



High Touch Healthcare Services Powered by Next Gen Technology

Our extraordinary care teams drive engagement, solve the Physician Gap, and fight for our members.



Care Advocates



Nurses



Nurse Case

Managers

Women's Health Nurses



Behavioral Health Clinician



Physicians (typically internal medicine or family practice)

Panel of 1000+ Physician Specialists


Medical Director Medical Records Specialist Provider Search Specialists Claims & Benefits Specialists Pharmacist & Pharmacist Tech

Dietician

Social Worker



The Physician Gap impact is real



Delayed and deferred doctor visits



Fragmented communication between providers (episodes)




Unnecessary surgeries and wrong treatments



We put doctors at the heart of the solution







Member



Single Point of Entry
ID card
Mobile app






Doctor-to-doctor




Benefits
Claims and appeals
DEI-focused provider search
Care & case management
Primary care
Mental health therapy
Expert medical opinion



Accolade fixes the Physician Gap



80% of visits occur same day



Data sharing with outside physicians

visit summaries and relevant data



Overall savings: 4%+

EMO: 25% of surgeries cancelled, 85% care plans improved



Our World-Class Technology

We use technology and data to seamlessly give members trust and human connection, every time.



Member Fingerprint



Call Scheduling



Skills-Based Routing



Automation



TrueHealth Actions



Αl



Trust and human connection, every time












The future state is connected for ease





Front door engagement








Actionable steps are given to member in app



True Health Actions Drive Personalized Care Experience

- A Concept Member Health Snapshot
- B Deployed Alerts
- Deployed True Health
 Action Recommendations




True Health Actions Create a Personalized Digital Experience



"For you"


Support call(s) to action (True Health Actions)




Member Driven user need

"Ways we can help"

Bring User Need resolution paths to front







What Al means at Accolade

Artificial Intelligence

A program and capabilities that can sense, reason, act, and adapt

Machine Learning

Algorithms whose performance improve as they are exposed to more data over time

Data Platform

Foundational multi-layered data architecture that is the proprietary source that powers our business



Our Al capabilities and utilization




Front Line Care Team

- Interaction Monitoring
- Auto QA Evaluations
- Auto Note Summarization
- Conversational Al across IVR and Messaging
- NextGen RPA & Workflow Automation
- Benefits & Claims Q&A



Clinical Intelligence

- Population Health
- Clinical Foundation Score
- EMO ML Models
- Decision & Workflow Engine




Analytics

- Clinical Analytics
- Workforce Management Forecasting
- NPS and CSAT Sentiment
- ML Engagement Prediction
- Gen Al Voice of Customer Trend & Insights Solution



Accolade's Advantages for the Healthcare Ecosystem





Today's Trusted Partner Ecosystem

High-quality solutions, complementary to Accolade's own, in categories that matter to our customers






Driving appropriate use of customers' programs is core to our value proposition

Ecosystem Programs

Existing point solutions



Benefit





FLCT training and referrals



Warm site connections



Referral reporting



Trusted Partner Ecosystem

Best-in-class solutions where customers enjoy easier purchasing and implementation, enhanced features, and incremental utilization











Billing

Partner vetting Streamlined Implementation ACCD-managed contracting

support

program eligibility management

Codeveloped FLCT training


ACCD-generated target outreach files promotion

Find Care

Closed loop reporting



Business Model Builds Momentum as Adoption Grows








Distribution Reach



Diversified customer profiles create opportunity and expand TAM



Direct

• Health Plan

Consumer

Government

• Ecosystem Partners

Business Model Builds Momentum as Adoption Grows



Improved Outcomes Across Conditions

	No True Health Action	One or more True Health Action	Improvement		
Musculoskeletal	AVOIDABLE ER VISITS				
57% members engaged 44% received 1+ Interventions	15%	13%	-13%		
Depression or Anxiety	OUTPATIENT BH VISITS (per member per year)				
47% members engaged 35% received 1+ Interventions	3.3	4.8	+47%		
SDoH Barriers	ANNUA	L WELLNES	S VISITS		
31% members engaged 21% received 1+ Interventions	47%	60%	+28%		





Financials



Accelerating Accolade's Innovation

Continuous investment in clinical transformation and operational excellence






IPO • July 2020

Follow-on Offering • October 2020

Convertible Debt Offering • March 2021



Significantly Expanded Addressable Market



\$216 billion TAM

\$170B

Primary Care

\$22B


Expert Medical Opinion

\$24B

Navigation & Advocacy




Consistent growth and progress toward profitability





Customer and revenue diversification



1200+ customers

- No 5% customer in FY24
- Broad industry diversification



Long-Term Goals

Financial Targets and Goals (Non-GAAP)

Adj. Gross Margin		50-55%
	P&T as % of Rev.	13–17%
Adj. Operating Expenses	S&M as % of Rev.	15-20%
	G&A as % of Rev.	7-9%
Adj. EBITDA Margin		15-20%

Refer to the Appendix for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures.



Growth, Scale & Profitability



Highly diversified revenue mix



Expanding margins and operating leverage



One Accolade driving operational efficiencies



Attractive and improving unit economics



Clear vision toward \$1B+ revenue and target financial model









Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA

Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation and severance costs. We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors, as they eliminate the impact of certain noncash expenses and allow a direct comparison of these measures between periods without the impact of noncash expenses and certain other nonrecurring operating expenses.

Adjusted EBITDA is a non-GAAP financial measure that we define as net income (loss) adjusted to exclude interest expense (income), net, income tax expense (benefit), depreciation and amortization, stock-based compensation, acquisition and integration-related costs, goodwill impairment, change in fair value of contingent consideration, severance costs, and other expense (income). Severance costs include severance payments related to the realignment of our resources. Other expense (income) includes debt extinguishment gain or loss and foreign exchange gain or loss. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance. We believe Adjusted EBITDA is useful in evaluating our operating performance compared to that of other companies in our industry, as this measure generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA have certain limitations, including that they exclude the impact of certain non-cash charges, such as depreciation and amortization, whereas underlying assets may need to be replaced and result in cash capital expenditures, and stock-based compensation expense, which is a recurring charge. These non-GAAP financial measures may also not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner, limiting their usefulness as comparative measures. In evaluating these non-GAAP financial measures, you should be aware that in the future we expect to incur expenses similar to the adjustments in this presentation. Our presentation of non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or nonrecurring items. When evaluating our performance, you should consider these non-GAAP financial measures alongside other financial performance measures, including the most directly comparable GAAP measures set forth in the reconciliation tables below and our other GAAP results

The following tables present, for the periods indicated, the calculation of our Adjusted Gross Profit and Adjusted Gross Margin:



Adjusted EBITDA (Loss) Reconciliation (\$ in thousands)

Fiscal year ended February 28 (29),	2020	2021	2022	2023	2024
Net Loss	\$ (51,365)	\$ (50,652)	\$ (123,124)	\$ (459,650)	\$ (99,805)
Adjusted for:					
Interest expense (income), net	2,925	3,724	2,905	(255)	(5,952)
Income tax expense (benefit)	129	4	(5,639)	(3,624)	1,235
Depreciation and amortization	8,516	8,212	42,608	46,377	45,164
Stock-based compensation	6,002	9,576	72,939	72,644	60,941
Acquisition & integration-related costs	567	2,050	13,219	1,218	(7)
Goodwill impairment				299,705	
Change in fair value of contingent consideration			(45,416)		
Severance costs				7,065	864
Other expense (income)	107	147	133	15	(9,931)
Adjusted EBITDA (Loss)	\$ (33,119)	\$ (26,939)	\$ (42,375)	\$ (36,505)	\$ (7,491)



^{*}Please refer to page 35 for important information regarding non-GAAP financial measures

Adjusted Gross Profit & Gross Margin Reconciliation (\$ in thousands)

iscal year ended February 28 (29),	2020	2021	2022	2023	2024
Revenue	\$ 132,507	\$ 170,358	\$ 310,021	\$ 363,142	\$ 414,292
Cost of revenue, excluding depreciation and amortization	(73,685)	(93,673)	(169,019)	(198,905)	(222,232)
Amortization of acquired intangible assets, cost of revenue	(846)	(1,450)	(26,971)	(28,075)	(28,048)
Depreciation of property and equipment, cost of revenue	(6,653)	(6,023)	(4,836)	(3,677)	(5,213)
GAAP Gross Profit	\$ 51,323	\$ 69,212	\$ 109,195	\$ 132,485	\$ 158,799
GAAP Gross Margin	38.7%	40.6%	35.2%	36.5%	38.3%
GAAP Gross Profit	\$ 51,323	\$ 69,212	\$ 109,195	\$ 132,485	\$ 158,799
Amortization of acquired intangible assets, cost of revenue	846	1,450	26,971	28,075	28,048
Depreciation of property and equipment, cost of revenue	6,653	6,023	4,836	3,677	5,213
Stock-based compensation, cost of revenue	318	948	3,197	4,794	4,309
Severance costs, costs of revenue	-	-	-	1,025	686
Adjusted Gross Profit	\$ 59,140	\$ 77,633	\$ 144,199	\$ 170,056	\$197,055
Adjusted Gross Margin	44.6%	45.6%	46.5%	46.8%	47.6%



^{*}Please refer to page 35 for important information regarding non-GAAP financial measures

Adjusted Operating Expense Reconciliation (\$ in thousands)

Fiscal year ended February 28 (29),	2020	2021	2022	2023	2024
Revenue	\$ 132,507	\$ 170,358	\$ 310,021	\$ 363,142	\$ 414,292
Operating Expenses Less:	107,026	123,462	266,727	627,751	306,513
Depreciation and amortization	(8,516)	(8,212)	(42,608)	(46,377)	(45,164)
Stock-based compensation	(5,684)	(8,628)	(69,742)	(67,850)	(56,632)
Acquisition, integration-related costs and other	(567)	(2,050)	(13,219)	(1,218)	7
Goodwill Impairment				(299,705)	
Change in fair value of contingent consideration			45,416		
Severance costs				(6,040)	(178)
Adjusted Operating Expenses	\$ 92,259	\$ 104,572	\$ 186,574	\$ 206,561	\$ 204,546
Adjusted Operating Expenses as a % of Revenue	70%	61%	60%	57%	49%



^{*}Please refer to page 35 for important information regarding non-GAAP financial measures

